Anilinoquinazoline inhibitors of fructose 1,6-bisphosphatase bind at a novel allosteric site: Synthesis, in vitro characterization, and x-ray crystallography

Journal of Medicinal Chemistry

Volumn 45, Issue 18, 2002, Pages 3865-3877

  Wright, Stephen W ^a   Carlo, Anthony A ^a   Carty, Maynard D ^a   Danley, Dennis E ^a   Hageman, David L ^a   Karam, George A ^a   Levy, Carolyn B ^a   Mansour, Mahmoud N ^a   Mathiowetz, Alan M ^a   McClure, Lester D ^a   Nestor, Nestor B ^a   McPherson, R Kirk ^a   Pandit, Jayvardhan ^a   Pustilnik, Leslie R ^a   Schulte, Gayle K ^a   Soeller, Walter C ^a   Treadway, Judith L ^a   Wan, Ing Kae ^a   Bauer, Paul H ^a  

^a PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

(2 CHLOROMETHYL 6,7 DIETHOXYQUINAZOLIN 4 YL)[3 (2 METHYLTHIAZOL 4 YL)PHENYL]AMINE; (2 DIMETHYLAMINOMETHYL 6,7 DIETHOXYQUINAZOLIN 4 YL)[3 (2 METHYLTHIAZOL 4 YL)PHENYL]AMINE; (6 ETHOXY 7 ISOPROPOXYQUINAZOLIN 4 YL)[3 (2 METHYLTHIAZOL 4 YL)PHENYL]AMINE; (6,7 DIETHOXYQUINAZOLIN 4 YL)(3 PYRIDIN 3 YLPHENYL)AMINE; (6,7 DIETHOXYQUINAZOLIN 4 YL)[3 (2 PHENYLTHIAZOL 4 YL)PHENYL]AMINE; (6,7 DIETHOXYQUINAZOLIN 4 YL)[4 FLUORO 3 (2 METHYLTHIAZOL 4 YL)PHENYL]AMINE; 2 [3 (6,7 DIETHOXYQUINAZOLIN 4 YLAMINO)PHENYL]THIAZOLE 4 CARBOXYLAMIDE; 4 [3 (6,7 DIETHOXYQUINAZOLIN 4 YLAMINO)PHENYL]THIAZOLE 2 CARBOXYLAMIDE; ANTIDIABETIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE; FRUCTOSE BISPHOSPHATASE; FRUCTOSE BISPHOSPHATASE INHIBITOR; QUINAZOLINE DERIVATIVE; UNCLASSIFIED DRUG;

ALLOSTERISM; ARTICLE; CHEMICAL MODIFICATION; DRUG BINDING; DRUG BINDING SITE; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME ACTIVE SITE; ENZYME BINDING; ENZYME INHIBITION; ENZYME SUBUNIT; MOLECULAR RECOGNITION; SITE DIRECTED MUTAGENESIS; STRUCTURE ACTIVITY RELATION; STRUCTURE ANALYSIS; X RAY CRYSTALLOGRAPHY;

ALLOSTERIC SITE; ANILINE COMPOUNDS; ANIMALS; CATALYTIC DOMAIN; CRYSTALLOGRAPHY, X-RAY; ENZYME INHIBITORS; FRUCTOSE-BISPHOSPHATASE; HUMANS; MODELS, MOLECULAR; MUTAGENESIS, SITE-DIRECTED; QUINAZOLINES; RABBITS; RATS; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0037194657     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm010496a     Document Type: Article

References (62)

1. Receptor and postreceptor defects contribute to the insulin resistance in noninsulin-dependent diabetes mellitus
2. The triumvirate: Beta cell, muscle, liver. A collusion responsible for NIDDM
3. 13C NMR
4. 13C nuclear magnetic resonance study
5. Predominant role of gluconeogenesis in increased hepatic glucose production in NIDDM
6. Relative contribution of glycogenolysis and gluconeogenesis to hepatic glucose production in control and diabetic rats. A reexamination in the presence of euglycaemia
7. Molecular physiology of the regulation of hepatic gluconeogenesis and glycolysis
8. Pathogenesis of hyperglycemia in genetically obese-hyperglycemic rats, wistar fatty: Presence of hepatic insulin resistance
9. A comparison of the effects of diabetes induced with either alloxan or streptozotocin and of starvation on the activities in rat liver of the key enzymes of gluconeogenesis
10. Intracellular concentration and specific activity of carbohydrate - Metabolizing enzymes. Application of specific radioimmunoassays
11. Molecular physiology of the regulation of hepatic gluconeogenesis and glycolysis
12. Inhibition of fructose-1,6-bisphosphatase by fructose 2,6-bisphosphate
13. Inhibition of fructose-1,6-bisphosphatase by fructose 2,6-bisphosphate
14. Hormonal regulation of hepatic gluconeogenesis and glycolysis
15. Allosteric inhibition of rat liver fructose 1,6-diphosphatase by adenosine 5′-monophosphate
16. Conformational transition of fructose-1,6-bisphosphatase: Structure comparison between the amp complex (T form) and the fructose 6-phosphate complex (R form)
17. Toward a mechanism for the allosteric transition of pig kidney fructose-1,6-bisphosphatase
18. The allosteric site of human liver fructose-1,6-bisphosphatase
19. Allosteric inhibition of fructose-1,6-bisphosphatase by anilinoquinazolines
20. Isolation of a human liver fuctose-1,6-bisphosphatase cDNA and expression of the protein in Escherichia coli
21. A malachite green procedure for orthophosphate determination its use in alkaline phosphatase-based enzyme immunoassay
22. cDNA sequence of rat liver fructose-1,6-bisphosphatase and evidence for down-regulation of its mRNA by insulin
23. Shared active sites of fructose-1,6-bisphosphatase
24. Fructose diphosphatase from rabbit liver
25. Fructose diphosphatase from rabbit liver. X. Isolation and kinetic properties of the enzyme-adenosine monophosphate complex
26. A specific inhibitor of the epidermal growth factor receptor tyrosine kinase
27. Directed mutations in the poorly defined region of porcine liver fructose-1,6-bisphosphatase signficicantly affect catalysis and the mechanism of AMP inhibition
28. Role of a dynamic loop in cation activation and allosteric regulation of recombinant porcine fructose1,6-bisphosphatase
29. Tryptophan fluorescence reveals the conformational state of a dynamic loop in recombinant porcine fructose-1,6-bisphosphatase
30. Mutations in the hinge of a dynamic loop broadly influence functional properties of fructose-1,6-bisphosphatase
31. The C1-C2 interface residue lysine 50 of pig kidney fructose-1,6-bisphosphatase has a crucial role in the cooperative signal transmission of the AMP inhibition
32. Crystal structure of fructose-1,6-bisphosphatase complexed with fructose 6-phosphate, AMP, and magnesium
33. Biochemical properties of mutant and wildtype fructose-1,6-bisphosphatases are consistent with the coupling of intra- and intersubunit conformational changes in the T- and R-state transition
34. On the attribution and additivity of binding energies
35. Human liver glycogen phosphorylase inhibitors bind at a new allosteric site
36. Drug-like properties and the causes of poor solubility and poor permeability
37. The allosteric site of human liver fructose-1,6-bisphosphatase
38. Characterization of the allosteric binding pocket of human liver fructose-1,6-bisphosphatase by protein crystallography and inhibitor activity studies
39. Quaternization of thiazoles
40. Quinolone antibacterials. 1. 7-(2-Substituted-4-thiazolyl- and -thiazolidinyl)quinolones
41. Cardiotonic agents. 2. Synthesis and structure-activity relationships in a new class of 6-, 7-, and 8-pyridyl-2(1h)-quinolone derivatives
42. Arylpyridines. Part 1. Phenylpyridines and nitrophenylpyridines
43. Arylpyridines. Part 4. 3- and 4-pyridyldiphenyls
44. A new synthesis of aliphatic aromatic thioamides from nitriles
45. The synthesis and antibacterial activities of quinolones containing five- and six-membered heterocyclic substituents at the 7-position
46. Oxygenation of 4-alkoxyl groups in alkoxybenzoic acids by Polyporus dichrous
47. Characterization and kinetic analysis of the intracellular domain of human protein tyrosine phosphatase beta using synthetic phosphópeptides
48. Expression of rat liver fructose-1,6-bisphosphatase in escherichia coli